Amman, Sept 14 (Petra) — The Jordan Food and Drug Administration
(JFDA) Director General Rana Obeidat reaffirmed on Monday the
agency’s commitment to supporting the domestic pharmaceutical
industry and enabling it to develop innovative, high-value products
to boost competitiveness and expand exports to regional and global
markets.

Speaking during a field visit to the Jordanian Pharmaceutical
Manufacturing Company (JPM) plant in Umm al-Amad to examine
production operations and growth opportunities, Obeidat emphasized
that the JFDA’s regulatory and supervisory role aims to elevate
product quality, support local manufacturing, and strengthen its
market presence at home and abroad.

She highlighted the need to keep pace with global pharmaceutical
advances, boost research and development (R&D), utilize advanced
technologies, and venture into promising fields such as natural and
herbal products and rapid diagnostic medical supplies to ensure
national health and drug security.

Obeidat called for establishing a collaborative network among
accredited R&D laboratories to analyze and develop medicines,
streamlining analytical and validation methods across the sector.

Hanan Al-Sboul, Secretary General of the Jordanian Association of
Pharmaceutical Manufacturers (JAPM), praised the JFDA’s role in
supporting the industry’s objectives under the Economic Modernization
Vision, particularly in job creation, boosting national exports, and
safeguarding national drug security.

JPM Chief Executive Officer Abdulhamid Sinokrot stressed the
importance of public-private partnerships in delivering safe,
effective, and high-quality medications while making local production
more responsive to market demands.

Sinokrot outlined JPM’s expansion plans, which include broadening its
product portfolio, moving into specialized manufacturing of
injectable and biological drugs, expanding strategic partnerships,
and facilitating technology transfer to solidify Jordanian
pharmaceuticals’ regional position.

The meeting was attended by JPM subsidiary General Manager Taha
Al-Kubaisi, Executive Advisor Mustafa Al-Kubaisi, JFDA Drug
Department Director Rana Malkawi, Inspector Rasheed Salah, and other
company and agency officials.

During the visit, Obeidat toured the manufacturing facilities to
review technical capabilities, quality control systems, and product
development workflows aimed at meeting local and export demand. The
tour forms part of a series of joint field visits conducted by the
JFDA and the JAPM to evaluate investment and sustainable growth
opportunities across the sector.

//Petra// AF